Recent studies have reported that sunitinib and sorafenib could suppress expression of VEGFR2 and hypoxia‐inducible factor (HIF)‐1α as well as decrease the number of tumor‐infiltrating Tregs in several carcinomas of humans, suggesting that these TKIs might target the TME.9, 10, 11, 12, 13 Consequently, we hypothesized that TOC also could therapeutically target the TME in dogs with adenocarcinoma, and could help improve long‐term TTP after surgery. Here, KDR is linked to adenocarcinoma.